Ser362

Site Information
GADCIMLsGEtAkGD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23132417

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	HER2 positive breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , esophageal cancer ( 4 ) , esophageal carcinoma ( 4 )
Relevant cell line - cell type - tissue:	breast ( 2 ) , HeLa (cervical) ( 1 , 3 ) , Kyse140 (esophageal) ( 4 )

Upstream Regulation
Treatments:	EGF ( 1 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
4	Tucker M (2010) CST Curation Set: 9225; Year: 2010; Biosample/Treatment: cell line, Kyse140/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info